Lv Yajuan, Zhang Jiandong, Liu Zhen, Liang Ning, Tian Yuan
Department of Radiology, Shandong Provincial Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China.
Mol Clin Oncol. 2018 Jul;9(1):70-74. doi: 10.3892/mco.2018.1622. Epub 2018 May 10.
The aim of the present study was to investigate the efficacy and life quality of temozolomide (TMZ) combined with whole-brain radiotherapy (WBRT) for patients with brain metastases (BM) from non-small-cell lung cancer (NSCLC). A total of 77 cases of patients with lung cancer and BM were selected and divided into two groups; the first group was administered WBRT with TMZ, and the second group was administered WBRT with placebo. The efficacy, overall survival (OS) and quality of life (QoL) were then compared between the two groups. There were no significant differences in toxicity between the two groups. However, the first group exhibited an advantage over the second group in terms of objective response and OS (P<0.5). Therefore, WBRT may improve the QoL of patients with BM. TMZ concomitantly with WBRT was well-tolerated and may be recommended for the treatment of BM from NSCLC.
本研究的目的是探讨替莫唑胺（TMZ）联合全脑放疗（WBRT）治疗非小细胞肺癌（NSCLC）脑转移（BM）患者的疗效和生活质量。共选取77例肺癌合并BM患者，分为两组；第一组给予WBRT联合TMZ，第二组给予WBRT联合安慰剂。然后比较两组的疗效、总生存期（OS）和生活质量（QoL）。两组之间的毒性无显著差异。然而，第一组在客观缓解率和OS方面优于第二组（P<0.5）。因此，WBRT可能改善BM患者的QoL。TMZ与WBRT联合应用耐受性良好，可推荐用于NSCLC脑转移的治疗。
